Nurix Therapeutics Inc (NRIX) Stock Price, Quote & News

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK)...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 660 5320

Fax: 415 525 4200

Website: www.nurixtx.com

Address:

1600 Sierra Point Parkway, Brisbane, United States

ChefBoyAreWeGonnaBeRich Jul. 17 at 2:59 PM

$FLY $FLNC $NRIX $PENG $SBSW added some today

1 · Reply

ChefBoyAreWeGonnaBeRich Jul. 15 at 7:44 PM

$NRIX $PENG adding on all dips, including today

0 · Reply

oaksapollo Jul. 15 at 5:58 PM

$NRIX We made it into ARK's "Big ideas 2026" report

0 · Reply

Ravbcentinal Jul. 14 at 8:43 PM

$NRIX

0 · Reply

ChefBoyAreWeGonnaBeRich Jul. 13 at 2:01 PM

$FLY $FLNC $NRIX $SBSW shake

0 · Reply

ChefBoyAreWeGonnaBeRich Jul. 10 at 2:11 PM

$NRIX under $22.5 looking spicy

0 · Reply

d_risk Jul. 10 at 2:43 AM

$NRIX - Nurix Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +313.7% above peer average (48,175 vs 11,646 across 654 peers). NRIX flags new execution and antitrust-closing risk around its big-ticket Roche bexobrutideg deal (and related $700M upfront/$2.3B potential economics), heightened uncertainty from evolving UK clinical/reimbursement rules, IRA and new Trump drug-tariff moves, plus escalating AI-driven cyber and privacy threats. #Biotechnology #PharmaceuticalPartnerships #AntitrustRisk #HealthcareRegulation #AICybersecurity 🟢 Added 🟠 Removed https://d-risk.ai/NRIX/10-Q/2026-07-09

0 · Reply

oaksapollo Jul. 9 at 8:09 PM

$NRIX They have a minimum of 2.5 years of runway after the Roche deal closes...nice.

0 · Reply

CH_Expat Jul. 8 at 6:33 PM

$DERM , $DBVT and $NRIX are the only serious candidates to bring some of my $CRNX profits to right now, but not for the current valuations. None of the names really thrill me. If the imevitable mega correction comes, I might also average up IDYA and MLYS

2 · Reply

ChefBoyAreWeGonnaBeRich Jul. 2 at 2:07 PM

$NRIX $PENG $DXYZ added more

0 · Reply

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

2026-07-13T11:50:47.000Z - 8 days ago

Nurix Therapeutics price target raised to $34 from $30 at Mizuho

2026-07-10T12:45:48.000Z - 11 days ago

Nurix Therapeutics price target raised to $34 from $32 at Truist

2026-07-10T12:45:35.000Z - 11 days ago

Nurix Therapeutics price target raised to $33 from $30 at RBC Capital

2026-07-10T11:20:35.000Z - 11 days ago

Nurix Therapeutics price target raised to $40 from $34 at Stifel

2026-07-10T10:05:23.000Z - 11 days ago

Nurix Therapeutics price target raised to $34 from $32 at H.C. Wainwright

2026-07-09T20:10:22.000Z - 12 days ago

Nurix Therapeutics reports Q2 EPS (81c), consensus (72c)

Jul 9, 2026, 4:01 PM EDT - 12 days ago

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jul 9, 2026, 7:00 AM EDT - 12 days ago

Nurix Therapeutics Earnings release: Q2 2026

Jul 9, 2026, 7:00 AM EDT - 12 days ago

Nurix Therapeutics Quarterly report: Q2 2026

2026-06-29T12:00:16.000Z - 22 days ago

Nurix Therapeutics assumed with an Outperform at Oppenheimer

2026-06-18T10:25:28.000Z - 4 weeks ago

Nurix Therapeutics price target raised to $33 from $26 at Baird

$Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy$

Jun 11, 2026, 7:00 AM EDT - 5 weeks ago

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

2026-06-09T13:28:40.000Z - 6 weeks ago

Nurix Therapeutics price target raised to $32 from $30 at Truist

2026-06-09T11:25:04.000Z - 6 weeks ago

Nurix Therapeutics price target raised to $32 from $30 at BTIG

2026-06-08T18:00:13.000Z - 6 weeks ago

Nurix Therapeutics price target raised to $32 from $30 at Truist

2026-06-08T17:31:03.000Z - 6 weeks ago

Nurix Therapeutics price target raised to $45 from $41 at Jefferies

2026-06-08T14:31:00.000Z - 6 weeks ago

Nurix Therapeutics price target raised to $34 from $26 at Needham

Jun 8, 2026, 10:08 AM EDT - 6 weeks ago

This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug

2026-06-08T14:00:42.000Z - 6 weeks ago

Nurix Therapeutics downgraded to Equal Weight at Wells Fargo after Roche deal

2026-06-08T13:56:19.000Z - 6 weeks ago

Nurix Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo

Jun 8, 2026, 8:00 AM EDT - 6 weeks ago

Nurix Therapeutics Transcript: Study update

Jun 8, 2026, 8:00 AM EDT - 6 weeks ago

Nurix Therapeutics Press release: Study update

Jun 8, 2026, 8:00 AM EDT - 6 weeks ago

Nurix Therapeutics Slides: Study update

2026-06-08T10:08:35.000Z - 6 weeks ago

Nurix Therapeutics Stock (NRIX) Soars 40% After $2.3B Blood Cancer Deal with Roche

2026-06-08T09:45:21.000Z - 6 weeks ago

Nurix Therapeutics teams with Roche to develop, commercialize bexobrutideg

Jun 8, 2026, 3:51 AM EDT - 6 weeks ago

Roche enters $2 billion cancer drug agreement with Nurix Therapeutics

Jun 8, 2026, 1:47 AM EDT - 6 weeks ago

Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics

Jun 8, 2026, 1:00 AM EDT - 6 weeks ago

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Jun 8, 2026, 1:00 AM EDT - 6 weeks ago

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

Jun 3, 2026, 11:05 AM EDT - 6 weeks ago

Nurix Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 20, 2026, 1:35 PM EDT - 2 months ago

Nurix Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 14, 2026, 4:05 PM EDT - 2 months ago

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

May 13, 2026, 7:00 AM EDT - 2 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

May 12, 2026, 4:05 PM EDT - 2 months ago

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

Apr 22, 2026, 7:00 AM EDT - 3 months ago

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Apr 13, 2026, 1:30 PM EDT - 3 months ago

Nurix Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 6:00 AM EDT - 3 months ago

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Apr 8, 2026, 6:00 AM EDT - 3 months ago

Nurix Therapeutics Earnings release: Q1 2026

Apr 8, 2026, 6:00 AM EDT - 3 months ago

Nurix Therapeutics Quarterly report: Q1 2026

Apr 7, 2026, 7:00 AM EDT - 3 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conference

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Nurix Therapeutics Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Nurix Therapeutics Proxy statement: Proxy filing

Mar 23, 2026, 4:05 PM EDT - 4 months ago

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

Feb 12, 2026, 12:00 PM EST - 5 months ago

Nurix Therapeutics Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Jan 28, 2026, 4:01 PM EST - 6 months ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

Jan 28, 2026, 4:00 PM EST - 6 months ago

Nurix Therapeutics Annual report: Q4 2025

Jan 28, 2026, 4:00 PM EST - 6 months ago

Nurix Therapeutics Earnings release: Q4 2025

Jan 12, 2026, 7:30 PM EST - 6 months ago

Nurix Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 PM EST - 6 months ago

Nurix Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 6 months ago

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

Jan 5, 2026, 7:00 AM EST - 7 months ago

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 8, 2025, 8:15 PM EST - 8 months ago

Nurix Therapeutics Transcript: Study Update

Dec 8, 2025, 8:15 PM EST - 8 months ago

Nurix Therapeutics Press release: Study Update

Dec 8, 2025, 8:00 AM EST - 8 months ago

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

$Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition$

Dec 6, 2025, 9:30 AM EST - 8 months ago

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Dec 3, 2025, 12:30 PM EST - 8 months ago

Nurix Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 8 months ago

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 25, 2025, 7:00 AM EST - 8 months ago

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 6:00 AM EST - 8 months ago

Nurix Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 9:20 AM EST - 8 months ago

Nurix Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 7:00 AM EST - 9 months ago

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nov 7, 2025, 9:00 AM EST - 9 months ago

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nov 3, 2025, 9:00 AM EST - 9 months ago

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 27, 2025, 7:00 AM EDT - 9 months ago

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Oct 22, 2025, 8:00 AM EDT - 9 months ago

Nurix Therapeutics Transcript: Study Update

Oct 22, 2025, 8:00 AM EDT - 9 months ago

Nurix Therapeutics Press release: Study Update

Oct 22, 2025, 8:00 AM EDT - 9 months ago

Nurix Therapeutics Slides: Study Update

Oct 22, 2025, 7:20 AM EDT - 9 months ago

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

$Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia$

Oct 22, 2025, 6:00 AM EDT - 9 months ago

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Oct 18, 2025, 3:00 AM EDT - 9 months ago

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Oct 9, 2025, 4:01 PM EDT - 10 months ago

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Oct 9, 2025, 4:00 PM EDT - 10 months ago

Nurix Therapeutics Earnings release: Q3 2025

Oct 9, 2025, 4:00 PM EDT - 10 months ago

Nurix Therapeutics Quarterly report: Q3 2025

Sep 17, 2025, 7:00 AM EDT - 10 months ago

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Sep 16, 2025, 11:00 AM EDT - 11 months ago

Nurix Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 10, 2025, 7:00 AM EDT - 11 months ago

Nurix Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 10:50 AM EDT - 11 months ago

Nurix Therapeutics Transcript: Baird Global Healthcare Conference 2025

Sep 8, 2025, 1:30 PM EDT - 11 months ago

Nurix Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 1:30 PM EDT - 11 months ago

Nurix Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 1:30 PM EDT - 11 months ago

Nurix Therapeutics Slides: FY 2025

Jul 9, 2025, 4:01 PM EDT - 1 year ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 9, 2025, 7:00 AM EDT - 1 year ago

Nurix Therapeutics Earnings release: Q2 2025

Jul 9, 2025, 7:00 AM EDT - 1 year ago

Nurix Therapeutics Quarterly report: Q2 2025

Jul 7, 2025, 7:00 AM EDT - 1 year ago

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Jun 13, 2025, 4:01 PM EDT - 1 year ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Transcript: Study Update

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Press release: Study Update

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Slides: Study Update

$Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)$

Jun 12, 2025, 7:00 AM EDT - 1 year ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Jun 6, 2025, 7:00 AM EDT - 1 year ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Jun 4, 2025, 3:45 PM EDT - 1 year ago

Nurix Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

May 28, 2025, 7:00 AM EDT - 1 year ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 21, 2025, 2:05 PM EDT - 1 year ago

Nurix Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:30 AM EDT - 1 year ago

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Apr 28, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Apr 8, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 8, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Quarterly report: Q1 2025

Apr 8, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Earnings release: Q1 2025

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Proxy statement: Proxy Filing

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Mar 13, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Mar 12, 2025, 10:00 AM EDT - 1 year ago

Nurix Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Feb 11, 2025, 12:40 PM EST - 1 year ago

Nurix Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 28, 2025, 4:00 PM EST - 1 year ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Jan 28, 2025, 4:00 PM EST - 1 year ago

Nurix Therapeutics Earnings release: Q4 2024

Jan 28, 2025, 4:00 PM EST - 1 year ago

Nurix Therapeutics Annual report: Q4 2024

ChefBoyAreWeGonnaBeRich Jul. 17 at 2:59 PM

$FLY $FLNC $NRIX $PENG $SBSW added some today

1 · Reply

ChefBoyAreWeGonnaBeRich Jul. 15 at 7:44 PM

$NRIX $PENG adding on all dips, including today

0 · Reply

oaksapollo Jul. 15 at 5:58 PM

$NRIX We made it into ARK's "Big ideas 2026" report

0 · Reply

Ravbcentinal Jul. 14 at 8:43 PM

$NRIX

0 · Reply

ChefBoyAreWeGonnaBeRich Jul. 13 at 2:01 PM

$FLY $FLNC $NRIX $SBSW shake

0 · Reply

ChefBoyAreWeGonnaBeRich Jul. 10 at 2:11 PM

$NRIX under $22.5 looking spicy

0 · Reply

d_risk Jul. 10 at 2:43 AM

0 · Reply

oaksapollo Jul. 9 at 8:09 PM

$NRIX They have a minimum of 2.5 years of runway after the Roche deal closes...nice.

0 · Reply

CH_Expat Jul. 8 at 6:33 PM

2 · Reply

ChefBoyAreWeGonnaBeRich Jul. 2 at 2:07 PM

$NRIX $PENG $DXYZ added more

0 · Reply

Investor_Scale Jul. 1 at 3:14 PM

$NRIX possible runner $IPW

0 · Reply

revuelto Jun. 29 at 5:40 PM

$NRIX 🎉

0 · Reply

Wigglyick Jun. 29 at 4:09 PM

$NRIX Oppenheimer rates it an Outperform

0 · Reply

LabPsycho Jun. 26 at 9:52 PM

$GLUE Looks like a 2.9 million share trade went through at 4pm. Several other protein degrader / molecular glue companies also had huge trade at 4pm ($ERAS $TNGX ). Money appears to be flowing into XBI. And select biotech buying accelerated maybe by 500 billion $$ freed up with recent sell off chip and A.I. sector? Considering this, I think GLUE is going to blow past this year's high of $25 very soon. Furthermore, in addition, I think $NRIX recent $700 million dollar upfront deal with Roche just massively raised the ticket price for any big pharma wanting to partner with leading protein degrader / molecular glue companies.

1 · Reply

OkIGuess Jun. 26 at 2:58 PM

$NRIX There was an entry at $16.50 a few days ago that I missed and I am kicking myself. Nice for all of you who got in early.

0 · Reply

BullJack Jun. 26 at 2:02 PM

$CGEM $KARD $NRIX shoulda just bought all three lol

0 · Reply

MadStockAlerts1 Jun. 26 at 6:46 AM

$NRIX won't give up any ground to the downside. Every time it dips, buyers step right back in. The moving averages are stacked and the uptrend is holding firm. See how it refuses to break? 📈

0 · Reply

Grouphome Jun. 25 at 9:24 PM

$NRIX

0 · Reply

topstockalerts Jun. 25 at 8:46 PM

$NRIX the market isn’t giving this much room to breathe lower.

0 · Reply

Malahyde Jun. 25 at 2:40 PM

$NRIX I support their lab in Texas, the most advanced lab I've ever seen.

0 · Reply

LabPsycho Jun. 25 at 2:31 PM

$NRIX @Pika_Capital that is how market makers gas light investors into not trusting their own instincts. $700 million is a whopping amount of money - and only for part of the . Not to be outdone, I expect $GLUE to be next with an eye popping collaboration.

0 · Reply

ChefBoyAreWeGonnaBeRich Jun. 25 at 2:28 PM

$NRIX and $AIIO holding up the account today

0 · Reply

Market Cap	2.40B
Revenue (ttm)	83.98M
Net Income (ttm)	-264.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-314.91%
Debt to Equity Ratio	0.00

Volume	961,200
Avg Vol	2,255,656
Day's Range	N/A - N/A
Shares Out	103.78M
Stochastic %K	38%
Beta	1.80
Analysts	Strong Sell
Price Target	$32.50